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Abstract. 
The leading cause of death from malignant tumors worldwide is lung cancer. Before the 
development of molecularly targeted therapy, chemotherapy with platinum-based doublets 
was considered as the standard first-line treatment in advanced non-small cell lung cancer 
(NSCLC) patients. The introduction of epidermal growth factor receptor-tyrosine kinase in-
hibitor (EGFR-TKI) has led to remarkable advances in the treatment of NSCLC. Two activat-
ing EGFR mutations (Exon 19 deletion and Exon 21 L858R mutation) have been correlated 
with dramatic responses to EGFR-TKI. Every effort should be made to identify the EGFR 
mutation status in NSCLC patients prior to the initial systemic treatment in order to select 
those who are most likely to benefit from EGFR-TKIs. At the present time, first-generation 
EGFR-TKIs are available for clinical use, including gefitinib and erlotinib. Gefitinib was the 
first drug developed as an EGFR-TKI for NSCLC treatment. Several randomized phase III 
studies revealed that gefitinib provided superior response rate, improved PFS, and less toxicity 
compared with doublet chemotherapy for advanced NSCLC with activating EGFR mutation. 
Currently, first-line treatment with gefitinib is used in metastatic NSCLC patients with tumor 
EGFR mutation. Gefitinib is also administered as salvage therapy for NSCLC patients previ-
ously treated with chemotherapy. The standard of care for previously untreated patients with 
EGFR mutation-negative or unknown status still remains platinum-based chemotherapy. In 
this article, we have reviewed the relevant clinical data regarding gefitinib as a molecularly 
targeted therapy for NSCLC. 
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 中文摘要 
  肺癌為全世界惡性腫瘤死亡率最高之癌症。在分子標靶治療發展出來以前，以
platinum 為主的合併化學藥物治療(doublets)是晚期非小細胞肺癌的第一線標準治療。自
從有了上皮細胞生長因素接收器 -酪胺酸酶抑制劑 (epidermal growth factor recep-
tor-tyrosine kinase inhibitor，EGFR-TKI)之後，非小細胞肺癌的治療便有了長足之進展。
EGFR 基因有 exon 19 突變(deletion)，或 exon 21 突變(L858R point mutation)之患者對
EGFR-TKI 的藥效反應相當地好。所以對於每一位非小細胞肺癌的患者，臨床醫師應該
要盡力去檢測出患者的 EGFR 基因之突變狀態，以找出適合 EGFR-TKI 治療之病人。第
一代的 EGFR-TKIs，包括 gefitinib 與 erlotinib。Gefitinib 是第一個發展出來治療非小細
胞肺癌的 EGFR-TKI。一些隨機分配之第三期臨床試驗顯示，gefitinib 與合併化學藥物
治療相比之下，對於有 EGFR 基因活化性突變的晚期非小細胞肺癌，具有較好的藥效反
應、較好的無疾病惡化存活期、及較少的副作用。目前，gefitinib 是具有 EGFR 基因突
變的晚期非小細胞肺癌之第一線治療藥物。Gefitinib 也可作為接受過化學治療的非小細
胞肺癌患者之挽救性治療。對於野生型 EGFR 之患者，或者是 EGFR 基因突變狀態不明
之患者，以 platinum 為主的合併化學藥物治療仍然是第一線標準治療。本篇文章回顧了
Gefitinib 作為分子標靶治療之相關臨床研究。 
 
關鍵字: gefitinib、非小細胞肺癌、上皮細胞生長因素接收器、酪胺酸酶抑制劑 
INTRODUCTION 
Lung cancer is the leading cause of death world-
wide arising from malignant tumors. Only approxi-
mately 15% of all lung cancer patients survived for 5 
years or more after diagnosis. More than 85% of lung 
cancer cases have the non-small cell lung cancer 
(NSCLC) subtype; most patients present with ad-
vanced lung cancer and their 2-year survival rate is 
only 10-15% [1,2]. Before the development of molec-
ularly targeted therapy, chemotherapy with platinum- 
based doublets was considered as the standard first- 
line treatment for advanced NSCLC. Chemotherapy 
has provided modest improvements in patient survival, 
but lung cancer patients generally still have a dismal 
prognosis. Considering the relative non-specificity 
and toxicity of chemotherapy, the development of 
novel therapeutic strategies is imperative. Over the 
last decade, molecularly targeted therapies such as 
gefitinib or erlotinib for NSCLC treatment have 
demonstrated remarkable advances, including im-
proved progression-free survival (PFS), overall sur-
vival (OS), and superior quality of life in certain pa-
tient populations [3-7]. 
The identification of several driver oncogenes re-
lated to tumor progression and lung cancer metastasis 
has resulted in the detection of several potential ther-
apeutic targets [2,3,6]. The first oncogenic driver mu-
tation emerged in 2004 with the detection of activating 
mutations in the tyrosine kinase domain of epidermal 
growth factor receptor (EGFR). The frequency of 
EGFR mutations in NSCLC patients has been reported 
to be approximately 5-30%, depending on the differ-
ent population [8-11]. It was observed that a higher 
incidence of EGFR mutations was detected in East 
Asians [12,13]. These mutations were identified pre-
dominantly in pulmonary adenocarcinomas. EGFR 
and its downstream signaling pathway have been ex-
tensively studied in recent years. Two activating 
EGFR mutations (Exon 19 deletion and Exon 21 
L858R point mutation) have been associated with 
dramatic responses to EGFR tyrosine kinase inhibitors  
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Figure 1. EGFR signal transduction pathway. The reactions of ligand-receptor and recep-
tor-receptor interactions activate intracellular signaling pathways that regulate cellu-
lar survival/apoptosis, proliferation, and other cellular functions that lead to the acti-
vation of malignant behaviors. EGFR monoclonal antibody binds to EGFR and inter-
feres with the binding of ligands (such as EGF). EGFR-TKIs (e.g. gefitinib) bind to 
the intracellular tyrosine kinase domain and inhibit signal transduction pathway. EGF 
= epidermal growth factor; EGFR = epidermal growth factor receptor; TKI = tyrosine 
kinase inhibitor 
 
 
(TKI), such as gefitinib or erlotinib [9,10,14]. They 
exhibited favorable toxicity profiles and convenience 
for use. Gefitinib was the first drug developed as an 
EGFR-TKI for NCSLC treatment [15]. The relevant 
clinical information regarding gefitinib as a molecu-
larly targeted therapy for NSCLC was reviewed in this 
article. 
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 SIGNAL TRANSDUCTION PATHWAY 
OF EGFR 
Epidermal growth factor receptors (EGFR) and 
ErbB receptors belong to the same subclass I of the 
receptor tyrosine kinase (TK) superfamily. This ErbB 
family comprises four structurally similar receptors, 
including ErbB1 (EGFR/HER1), ErbB2 (HER2/Neu), 
ErbB3 (HER3), and ErbB4 (HER4) [16,17]. Of these 
four receptors, EGFR was the first to be identified. 
These receptors contain an extracellular domain for 
the binding of ligands, a transmembrane domain, and 
an intracellular TK domain. The binding of ligands to 
the extracellular domain of EGFR results in dimeriza-
tion of two receptor molecules, and activates receptor 
autophosphorylation through TK activity. Then, auto-
phosphorylation activates several downstream signal-
ing pathways which may lead to tumor proliferation, 
migration, metastasis, and inhibition of apoptosis 
[16-18]. 
The TK family consists of two main intracellular 
signal transduction pathways. One of them is the 
Ras-Raf-MEK-MAPK pathway which regulates gene 
transcription, and proliferation of tumor cells. The 
other crucial downstream pathway is the phosphati-
dylinositol 3-kinase (PI3K) -Akt pathway, which acti-
vates a series of reactions including cell proliferation, 
growth, and blocking apoptosis. Another signaling 
route is through the Janus kinase/signal transducers 
and activators of transcription (Jak/Stat) pathway 
[17,18]. When all of the pathways are activated, it may 
ultimately contribute to various cellular reactions 
containing cell growth, division, repair, survival (or 
apoptosis), adhesion, invasion, and metastasis.  
 
EGFR INHIBITION 
In 1981, Mendelsohn and colleagues reported that 
EGFR is often overexpressed in the human cancer cell, 
and is related to a poor outcome. Thus, they proposed 
the theory of a targeted cancer therapy through EGFR 
inhibition [19]. The previous studies reported that the 
frequency of EGFR overexpression in NSCLC speci-
mens was around 43% to 89% depending on different 
populations, detection techniques, and the definition 
of EGFR overexpression [20-24]. However, in these 
studies, the association between EGFR expression and 
survival benefit revealed controversial results [24,25]. 
In these studies, several strategies were applied for 
targeting the EGFR. Among them, EGFR-TKIs and 
monoclonal antibodies (MoAbs) were most frequently 
used in clinical applications [1,2,4,26]. Small mole-
cule TKIs bind to the intracellular TK domain of 
EGFR and interfere with signal transduction. MoAbs 
target the extracellular domain of EGFR and interfere 
with receptor signaling. EGFR-TKIs and MoAbs seem 
to possess similar effects with regard to receptor-  
dependent downstream signal transduction pathways, 
including the MAPK and PI3K-Akt pathways. Both of 
them lead to the effective inhibition of the major 
EGFR signaling pathways [27,28]. Therefore, EGFR- 
TKIs and MoAbs exhibit their anticancer effect in 
NSCLC patients by blocking several crucial cellular 
functions regulated by the EGFR, including cell-cycle 
arrest, cell apoptosis, blockade of cancer cell invasion 
and metastasis (Figure 1) [27,29,30]. After the discov-
ery of an intimate association between the efficacy of 
EGFR-TKIs and activating EGFR mutations, the 
EGFR-TKIs as targeted therapies for EGFR-mutant 
NSCLC have been intensively studied [2-4]. Never-
theless, anti-EGFR monoclonal antibodies (e.g. ce-
tuximab) have been studied less extensively and have 
demonstrated improved outcomes in merely one ran-
domized phase III study of cetuximab added to dou-
blet chemotherapy for treatment in chemotherapy- 
naïve NSCLC patients [2-4,31]. 
 
FIRST-GENERATION EGFR-TKI 
First-generation EGFR-TKIs include gefitinib 
(Iressa) and erlotinib (Tarceva). Both have been ap-
proved for the treatment of advanced NSCLC, and are 
orally administered small molecules that reversibly 
inhibit the EGFR tyrosine kinase and interfere with 
downstream signaling. Their side effects (like dose- 
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 dependent skin rash and diarrhea) are usually mild to 
moderate, and manageable in the outpatient depart-
ment under close monitoring. The first drug developed 
as an EGFR-TKI for NSCLC treatment was gefitinib 
[2,3,15]. In the phase I trial, gefitinib has demonstrat-
ed objective responses in NSCLC patients who were 
heavily treated with prior extensive rounds of chemo-
therapy or chemoradiotherapy, when administered as a 
single agent [32]. Two randomized multicenter phase 
II studies [Iressa Dose Evaluation in Advanced Lung 
Cancer 1 (IDEAL 1) and 2 (IDEAL 2)] have been 
conducted in patients with locally advanced or meta-
static NSCLC who had progressive disease after prior 
chemotherapy, including platinum-based and docetaxel- 
based therapies in order to evaluate the safety and ef-
ficacy of two oral doses of gefitinib (250 and 500 
mg/day) [33,34]. In the IDEAL 1 trial, a response rate 
of 18.7% and remarkably improved disease-related 
symptoms were demonstrated. Gefitinib at 250 mg/ 
day was as effective as 500 mg/day, and exhibited the 
superior toxicity profiles [33]. The IDEAL 2 trial re-
vealed 12% objective response rates in the 250 mg/d 
group, and 9% in the 500 mg/d group. Similar toxicity 
profiles had been observed in the IDEAL 1 and IDE-
AL 2 studies [33,34]. Based on these trials, The US 
Food and Drug Administration (FDA) approved ge-
fitinib as a third-line treatment for locally advanced or 
metastatic NSCLC patients after failure of platinum- 
and docetaxel-based chemotherapies in 2003 [18]. 
The ISEL (Iressa Survival Evaluation in Lung 
Cancer) trial requested by the US FDA was a ran-
domized phase III study designed to evaluate the sur-
vival benefit of gefitinib [35]. In this study, 1692 pa-
tients with previously treated advanced NSCLC were 
randomized to either gefitinib treatment or placebo, 
and gefitinib did not demonstrate statistically longer 
survival time compared with the placebo among all 
patients (median survival: 5.6 vs. 5.1 months; p = 
0.087). Nevertheless, preplanned subgroup analyses 
revealed that Asian patients receiving gefitinib (n = 
235) had significantly longer survival as compared 
with those receiving placebo (n = 107) (median sur-
vival: 9.5 vs. 5.5 months; p = 0.01). Significantly 
longer survival was also observed in patients who 
never smoked receiving gefitinib (n = 250) than those 
receiving a placebo (n = 125) (median survival: 8.9 vs. 
6.1 months; p = 0.012). In 2005, the US FDA limited 
the use of gefitinib to patients continuing to derive 
benefit from gefitinib prescribed previously or those 
enrolled in the clinical trial, because the lack of sur-
vival benefit that was demonstrated in the ISEL study 
[15,18]. 
A multicenter phase III randomized trial [Iressa 
NSCLC Trial Evaluating Response and Survival ver-
sus Taxotere (INTEREST)] with a non-inferiority de-
sign to compare gefitinib with docetaxel recruited 
1433 advanced NSCLC patients receiving at least one 
line of platinum-based chemotherapy. In this INTER-
EST trial, the results revealed the non-inferiority of 
gefitinib over docetaxel in terms of overall survival 
[median survival: 7.6 vs. 8.0 months; hazard ratio 
(HR): 1.020; 96% confidence interval (CI): 0.905- 
1.150], and suggested that gefitinib is an efficacious 
therapy in previously treated patients with molecularly 
unselected advanced NSCLC [36].  
In the subgroup analyses of the ISEL study de-
scribed above [35], gefitinib demonstrated significant 
survival benefits in East Asian patients, and those who 
had never smoked. Therefore, the Iressa Pan-Asia 
Study (IPASS) was initiated to evaluate the efficacy of 
gefitinib in East Asian patients [5]. The IPASS trial 
was the first randomized phase III trial to compare 
EGFR-TKI (gefitinib) with doublet chemotherapy 
(paclitaxel plus carboplatin) as first-line therapy in 
selected East Asia patients who were former light 
smokers or non-smokers with advanced pulmonary 
adenocarcinoma. In this study, 1217 patients were en-
rolled, and 437 patients (35.9%) received EGFR mu-
tation analysis. In a subgroup including 261 cases with 
EGFR mutation positive tumor, patients who received 
gefitinib had significantly longer progression-free 
survival (PFS) than those receiving paclitaxel plus  
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 Table 1. Phase III randomized trials comparing first-line EGFR-TKI with chemotherapy in clinically or 
molecularly selected NSCLC patients with activating EGFR mutations 
I-PASS NEJ002 WJTOG3405 OPTIMAL (CTONG-0802) EURTAC 
  G P + Cb (p*) G P + Cb (p*) G D + Cis (p*) E Ge + Cb (p*) E Platinum based ( p*)
RR (%) 71.2 47.3 (<0.001) 73.7 30.7 (<0.001) 62.1 32.2 (<0.0001) 83 36 (<0.001) 54.5 10.5 
CR (%) NA NA 4.4 0 NA NA 2 0 3 0 
PFS (mo) 9.5 4.9 (<0.001) 10.8 5.4 (<0.001) 9.2 6.3 (<0.0001) 13.1 4.6 (<0.001) 9.7 5.2 (<0.001) 
OS (mo) 21.6 21.9 (0.99) 30.5 23.6 (0.31) 34.8 37.3  22.7 28.8 (0.69) 19.3 19.5 (0.87) 
*The p values: when comparing with EGFR-TKI group  
Cb = carboplatin; Cis = cisplatin; CTONG = Chinese Thoracic Oncology Group; D = docetaxel; E = erlotinib; EGFR = epidermal growth factor receptor; EURTAC = 
European Tarceva versus chemotherapy; G = gefitinib; Ge = gemcitabine; I-PASS = Iressa Pan Asia study; NA = not applicable; NEJ002 = North East Japan 002; NSCLC 
= non-small-cell lung cancer; OPTIMAL = Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive NSCLC; OS = overall 
survival; P = paclitaxel; PFS = progression-free survival; RR = response rate; TKI = tyrosine kinase inhibitor; WJTOG3405 = West Japan thoracic oncology group 3405
 
carboplatin (HR: 0.48; 95% CI: 0.36-0.64; p < 0.001). 
However, in another subgroup including 176 patients 
without EGFR mutation, PFS was significantly shorter 
among patients who received gefitinib than those who 
received paclitaxel plus carboplatin (HR: 2.85; 95% 
CI: 2.05-3.98; p < 0.001).This trial suggested that the 
existence of tumor EGFR mutations is an important 
predictor of better outcome in patients receiving ge-
fitinib. The importance of identifying the EGFR muta-
tion status before deciding on initial treatment was 
first discovered in the IPASS trial [5,37]. Similar re-
sults were further confirmed in other phase III trials 
that revealed a significantly improved PFS and better 
quality of life in patients receiving EGFR-TKI as 
compared with platinum-based doublet chemotherapy 
(Table 1) [5,38-42]. A phase III randomized trial 
(WJTOG 3405) of gefitinib compared with cisplatin/ 
docetaxel as first-line treatment for EGFR-mutant 
NSCLC revealed that gefitinib provided a 3-year sur-
vival benefit for EGFR-mutant advanced NSCLC af-
ter 5 years of follow-up (median survival: 34.8 vs. 
37.3 months; HR: 1.252; 95% CI: 0.883-1.775 ), alt-
hough no significant difference in overall survival was 
observed [38,39]. 
In 2009, mainly based on results from IPASS and 
INTEREST trial, the European Medicines Agency 
(EMA) approved gefitinib as a targeted therapy for 
locally advanced or metastatic NSCLC harboring ac-
tivating EGFR mutation [43,44]. Gefitinib is also ap-
proved for use in Japan, Taiwan, China, Korea, and 
several Asian countries [18,43]. 
 
GEFITINIB COMBINED WITH 
CHEMOTHERAPY 
Previous reports suggest that gefitinib does not 
induce myelosuppression, which was found in patients 
receiving conventional chemotherapy [17,32-35]. In 
order to evaluate whether the addition of EGFR-TKI 
to chemotherapy can enhance the antitumor effect and 
provide longer survival than chemotherapy alone, four 
phase III trials in previously untreated patients with 
advanced NSCLC were initiated (Table 2) [45-48]. 
The INTACT (Iressa NSCLC Trial Assessing Combi-
nation Treatment) 1 trial enrolled 1093 patients who 
were randomized to chemotherapy (gemcitabine/  
cisplatin) with either gefitinib 250 mg/day, gefitinib 
500 mg/day, or placebo. No significantly different re-
sponse rate, time to progression, and overall survival 
was observed among these treatment groups. The 
INTACT 2 study with the design similar to INTACT 1 
recruited 1037 patients, and the chemotherapy regi-
men was carboplatin and paclitaxel [46]. The results 
also showed no significantly different response rate, 
time to progression, and overall survival among dif-
ferent treatment groups. The addition of Erlotinib to 
chemotherapy has also been evaluated, like gefitinib. 
In the TRIBUTE (Tarceva Responses in Conjunction 
with Paclitaxel and Carboplatin) and TALENT (Tarce-
va Lung Cancer Investigation) studies, chemotherapy- 
naïve NSCLC patients received chemotherapy both 
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 Table 2. Four randomized Phase III trials of chemotherapy with or without EGFR-TKI (gefitinib or erlotinib) 
in clinical or molecularly-unselected patients with treatment-naïve advanced NSCLC (A total of 4361 
patients) 
Trial No. of patients  Treatment comparison Response rate (%) PFS (mo) OS (mo) 
INTACT 1 1093 Cis + gemcitabine, or with gefitinib
 (250 or 500 mg/d) 
44.8 vs. 50.3 vs. 49.7 6.0 vs. 5.8 vs. 5.5 
 (p = 0.76) 
10.9 vs. 9.9 vs. 9.9  
(p = 0.45) 
INTACT 2 1037 Cb + paclitaxel, or with geitinib 
 (250 or 500 mg/d) 
42 vs. 41 vs. 37 5.0 vs. 5.3 vs. 4.6 
 (p = 0.562) 
9.9 vs. 9.8 vs. 8.7  
(p = 0.64) 
TRIBUTE 1059 Cb + paclitaxel, or with erlotinib 19.3 vs. 21.5 4.9 vs. 5.1 (p = 0.36) 10.5 vs. 10.6 (p = 0.95)
TALENT 1172 Cis + gemcitabine, or with erlotinib 29.9 vs. 31.5 5.7 vs. 5.5 (p = 0.74) 10.3 vs. 10.0 (p = 0.49)
Cb = carboplatin; Cis = cisplatin; INTACT = Iressa NSCLC Trial Assessing Combination Treatment; NSCLC = non-small-cell lung cancer; PFS = progression-free sur-
vival; OS = overall survival; TALENT = Tarceva Lung Cancer Investigation; TKI = tyrosine kinase inhibitor; TRIBUTE = Tarceva Responses in Conjunction with 
Paclitaxel and Carboplatin 
 
 
with and without erlotinib [47,48]. These trials also 
failed to demonstrate improved survival in patients 
receiving combination therapy with chemotherapy 
plus erlotinib. The above-mentioned four randomized 
phase III studies, including 4361 patients with chemo- 
naïve NSCLC, obviously revealed that the combina-
tion of EGFR-TKIs (gefitinib or erlotinib) with chem-
otherapy does not provide superior survival benefit 
over chemotherapy alone. Therefore, gefitinib should 
not be added to cytotoxic chemotherapy as the 
first-line treatment in molecularly unselected NSCLC 
patients [2,3]. 
 
EGFR MUTATION 
Previous studies have demonstrated that EGFR 
mutations may predict treatment response to EGFR- 
TKIs and also be a prognostic factor [17,47,49-53]. 
Cappuzzo and colleagues analyzed tumor specimens of 
NSCLC from 102 patients receiving gefitinib for tumor 
EGFR status by fluorescence in-situ hybridization 
(FISH), and immunohistochemistry, and for EGFR 
mutation by DNA sequencing [49]. The results re-
vealed the tumor EGFR status and mutation were cor-
related with treatment response and patient survival 
[2,3,49]. EGFR mutation status possessed the best cor-
relation with treatment effect [3,9,10,17,54], followed 
by FISH assay [49,54]. Several large serial studies on 
the epidemiology of EGFR mutation revealed that the 
reported mutations were all somatic and identified in 
exons 18, 19, 20, and 21 of the EGFR gene encoding 
partial intracellular TK domain of EGFR [13,55,56]. 
Prior studies also reported that the sensitivity to 
EGFR-TKIs was correlated with three kinds of EGFR 
mutations, including (1) in-frame deletions within exon 
19, accounting for approximately 46% of all EGFR 
mutations (the most common EGFR mutations); (2) 
missense mutations within exon 18, 20, or 21, ac-
counting for approximately 41% of all mutations (the 
second most common EGFR mutations), especially 
L858R point mutations within exon 21; and (3) 
in-frame duplications and/or insertions within exon 20 
(approximately 5% of all mutations) [2,13,55]. In addi-
tion to EGFR mutations, East Asian descent, female 
sex, never-smoker, and adenocarcinoma histology have 
also been reported to have a correlation with sensitivity 
to EGFR-TKIs. Another large study that enrolled 
12,244 patients revealed that the most common muta-
tions were exon 19 mutation (50%), followed by exon 
21 (40%), exon 20 (6%), and exon 18 (4%) mutations. 
L858R in exon 21 and deletion of E746-A750 in exon 
19 accounted for approximately 33% and 24% of all 
mutations [56]. An obvious correlation between the 
response to EGFR-TKIs and EGFR mutations has 
been reported. The best response rate (around 70%) 
was demonstrated in NSCLC patients with exon 19 
mutations, followed by those with exon 21, 18, and 20 
mutations ( approximately 20% or slightly higher). 
EGFR-mutant NSCLC patients receiving EGFR-TKI 
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 Table 3. Six phase III trials of maintenance therapy with EGFR-TKIs after first line chemotherapy (A total of 
3006 patients) 
Trial No. of patients Maintenance treatment Median PFS  p-value Median OS (mo) p-value 
WJTOG 0203 595 Gefitinib vs. observation 4.6 vs. 4.3 months <0.001 13.7 vs. 12.9 0.11 
EORTC 08021-ILCP 01/03 173 Gefitinib vs. placebo 4.1 vs. 2.9 months 0.002 10.9 vs. 9.4 0.204 
INFORM 296 Gefitinib vs. placebo 4.8 vs. 2.6 months <0.0001 18.7 vs. 16.9 0.26 
SATURN 889 Erlotinib vs. placebo 12.3 vs. 11.1 weeks <0.0001 12 vs. 11 0.0088 
ATLAS 743 Bevacizumab + erlotinib vs.
Bevacizumab + placebo 
4.8 vs. 3.7 months 0.001 14.4 vs. 13.3 0.5604 
IFCT-GFPC 0502a 310 Erlotinib vs. observation 2.9 vs. 1.9 months 0.003 11.4 vs. 10.8 0.3043 
Abbreviations: ATLAS =Avastin Tarceva Lung Adenocarcinoma Study; EGFR = epidermal growth factor receptor; EORTC = European Organization for Research and 
Treatment of Cancer; IFCT-GFPC = Intergroupe Francophone de Cancerologie Thoracique–Groupe Francais de Pneumo-Cancerologie; ILCP = Italian Lung Cancer
Project; OS = overall survival; PFS = progression-free survival; TKI = tyrosine kinase inhibitor; SATURN = Sequential Tarceva in Unresectable Non–Small-Cell Lung 
Cancer; WJTOG = West Japan Thoracic Oncology Group 
aIFCT-GFPC 0502 was a trial with 3 arms, including maintenance gemcitabine, maintenance erlotinib, and observation group
 
 
had median PFS of about 10 months. The PFS varied 
widely because of several potential mechanisms, in-
cluding T790M mutation, BIM polymorphism, c-Met 
amplification, and alterations within chromosome 7p, 
and even the percentage of EGFR mutation-negative 
cancer cells [2-4,57-62]. 
Several methods are utilized to identify EGFR 
mutations in tumor specimens from lung cancer pa-
tients, including direct sequencing, Scorpion ARMS 
(amplified refractory mutation system), and PNA- 
LNA (peptide nucleic acid-locked nucleic acid) PCR 
(polymerase chain reaction) clamp techniques [5, 
63-66]. The sensitivity of direct sequencing is rela-
tively low and it needs a higher percentage of mutant 
DNA in order to detect EGFR mutations in tumor 
specimens (10-25% mutant DNA). Therefore, objec-
tive response rates of 10-20% or higher in particular 
clinical populations receiving EGFR-TKI were re-
ported in EGFR wild type NSCLC patients whose 
EGFR mutation status was detected by the direct DNA 
sequencing method [67-69]. High-sensitivity methods, 
including Scorpion ARMS and PNA-LNA PCR clamp 
techniques, are capable of detecting ≥1% mutant DNA 
[5,63-65]. However, the Scorpion ARMS and 
PNA-LNA PCR clamp techniques are only able to 
identify recognized mutations, but direct sequencing is 
capable of detecting new mutations [63-66]. Tumor 
specimens used for EGFR mutation assessment are 
commonly collected from biopsies in the detected 
pulmonary or metastatic tumors. Specimens obtained 
from pleural effusion, plasma-free DNA, and circu-
lating tumor cells may also be utilized for EGFR mu-
tation assessment [63,64,66,70-73]. 
 
FIRST-LINE GEFITINIB 
TREATMENT FOR 
EGFR-MUTANT NSCLC 
First-line treatment with EGFR-TKIs for EGFR 
-mutant NSCLC has demonstrated improved PFS, 
better quality of life, and less treatment-related toxici-
ty compared with platinum-based doublet chemother-
apy in several recent randomized phase III studies 
(Table 1) [5,38-42]. Thus, EGFR mutation analysis for 
advanced NSCLC patients being considered for 
first-line EGFR-TKI should be performed, and ge-
fitinib as first-line treatment is recommended for 
NSCLC patients with activating EGFR mutation [74]. 
EGFR-mutant NSCLC patients receiving EGFR-TKI 
had median PFS of around 10 months. When first-line 
platinum-based doublet chemotherapy was used for 
EGFR-mutant NSCLC, the median PFS was only 5-6 
months. However, no significant difference in overall 
survival was found between EGFR-mutant patients 
receiving EGFR-TKI and those receiving first-line 
chemotherapy [41,75-78]. In patients with EGFR mu-
tation-negative or unknown status, first-line treatment 
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 with chemotherapy is preferred. First-line EGFR-TKIs 
in NSCLC patients with EGFR mutation-negative or 
unknown status might have a detrimental effect on 
PFS and OS [5,79,80]. 
In spite of the initial successful treatment with ge-
fitinib in EGFR-mutant NSCLC patients, most of 
them will eventually experience progressive disease 
(acquired resistance to gefitinib) [81]. Strategies for 
overcoming acquired resistance to gefitinib are being 
developed [2,3,57]. At the present time, a number of 
treatment choices are available after failure of ge-
fitinib treatment, such as salvage chemotherapy, use of 
another approved EGFR-TKI, participating in clinical 
studies with second-line molecularly targeted therapy, 
or chemotherapy with continuation of the EGFR-TKI 
already initiated. Of the above-mentioned therapeutic 
choices, only salvage chemotherapy is regarded as a 
standard of care or a preferred option after failure of 
gefitinib [2-4]. 
 
GEFITINIB AS MAINTENANCE 
TREATMENT AFTER FIRST-LINE 
CHEMOTHERAPY 
The strategy of maintenance therapy with EGFR- 
TKIs after first-line treatment has been assessed in 
several trials. Two phase III trials with molecularly 
unselected patients have demonstrated that gefitinib 
was not indicated as a maintenance or an adjuvant 
therapy in stage III patients after chemoradiotherapy 
or in patients with completely resected NSCLC 
[82,83]. In a retrospective study with resected stage I 
to III pulmonary adenocarcinoma patients harboring 
EGFR exon 19 deletions or exon 21 L858R mutation, 
a tendency toward improved disease-free survival was 
discovered in patients receiving adjuvant treatment 
with gefitinib or erlotinib compared with those who 
did not receive similar treatment [84]. Nevertheless, 
additional investigation is warranted to verify the 
above-mentioned results.  
A number of phase III trials in clinically or molec-
ularly unselected patients with advanced NSCLC have 
also revealed that gefitinib was not indicated for com-
bined treatment with EGFR-TKI and chemotherapy 
followed by a maintenance therapy with EGFR-TKI 
alone (Table 2) [45-48]. However, whether an interca-
lated combination of EGFR-TKI and chemotherapy 
provides clinical benefit remains debatable [85-87]. 
Switch maintenance therapy with EGFR-TKIs after 
first-line chemotherapy has been evaluated in 6 phase 
III trials (Table 3) [88-94]. In the West Japan Thoracic 
Oncology Group trial (WJTOG0203), advanced 
NSCLC patients were randomized to 6 cycles of dou-
blet chemotherapy or 3 cycles of chemotherapy fol-
lowed by gefitinib until the disease progressed [88]. 
Significantly improved PFS was observed in the pa-
tients receiving chemotherapy followed by gefitinib 
compared with those receiving chemotherapy alone, 
although no significant difference in OS was demon-
strated. Erlotinib has also been evaluated as a mainte-
nance treatment in the Sequential Tarceva in Unresec-
table NSCLC (SATURN) trial including 889 molecu-
larly unselected NSCLC patients without progressive 
disease after doublet chemotherapy for 4 cycles [91]. 
Erlotinib maintenance therapy yielded significant im-
provement in PFS (HR: 0.71; p< 0.0001), and overall 
survival compared with placebo (median survival: 12 
vs. 11 months; p = 0.0088). Similar results were 
demonstrated in the other studies [92-94].  
Similar to the SATURN study, the Iressa in 
NSCLC for maintenance (INFORM) trial revealed 
that the gefitinib maintenance therapy provided longer 
median PFS than placebo (4.8 vs. 2.6 months; p< 
0.0001), but no significant difference in OS was ob-
served. The PFS of patients receiving gefitinib 
maintenance therapy was significantly improved in the 
EGFR-mutant patients (HR: 0.17; 95% CI: 0.07-0.42), 
but not in EGFR mutation-negative patients (HR: 0.86, 
95% CI: 0.48-1.51). In patients with squamous cell 
carcinoma, no improvement in PFS was also found. 
The gefitinib maintenance treatment demonstrated a 
greater benefit in patients with activating EGFR muta-
tion [88,91,95]. 
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 ADVERSE EFFECTS OF 
GEFITINIB 
The main adverse reactions of gefitinib are der-
matologic and gastrointestinal toxicities, including 
skin rash/acneiform rashes (29-66%), dry skin 
(15-31%), pruritus (19-45%), paronychia (1-14%), 
diarrhea (16-47%), and elevated aminotransferase 
(11-26%) [5,33,35,36,42,76]. Most toxicities were 
usually mild to moderate. In the IPASS trial, neutro-
penia (3.7%) and anemia (2.2%) have been reported 
[5]. Interstitial lung disease (ILD) related to gefitinib 
has also been observed. An analysis of 50,005 patients 
initiated by the US FDA revealed that the worldwide 
incidence of ILD related to gefitinib treatment was 
approximately 1% [higher in Japan (2%) than in USA 
(0.3%)], and about one-third of these cases were lethal 
[96,97]. In a number of recent phase III trial, the re-
ported incidence of ILD ranged from 1.3 to 5.3 % 
[5,38,40,76]. Gefitinib treatment clearly demonstrated 
a favorable toxicity profile compared with doublet 
chemotherapy. 
 
CONCLUSIONS 
Gefitinib provides better response rate, improved 
PFS, and less toxicity compared with platinum-based 
doublet chemotherapy for advanced NSCLC with ac-
tivating EGFR mutation. Every effort should be made 
to identify the EGFR mutation status before the initial 
systemic therapy for NSCLC patients. First-line 
treatment with EGFR-TKI, including gefitinib or erlo-
tinib, should be used in patients with EGFR-mutant 
advanced NSCLC. For patients with unknown EGFR 
mutation status and poor performance status (PS 3-4), 
standard chemotherapy is an inappropriate treatment, 
so EGFR-TKI as first-line therapy could be consid-
ered for them. EGFR-mutant NSCLC patients receiv-
ing gefitinib had median PFS of approximately 10 
months. Further investigations about gefitinib are 
mandatory in order to develop better treatment strate-
gies and optimal therapy for each patient.  
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